Evrysdi FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 13, 2025.
FDA Approved: Yes (First approved August 7, 2020)
Brand name: Evrysdi
Generic name: risdiplam
Dosage form: Powder for Oral Solution and Oral Tablets
Company: Genentech, Inc.
Treatment for: Spinal Muscular Atrophy
Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Development timeline for Evrysdi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.